Dr Tiina Palomäki has been working as a senior researcher at the Finnish medicines agency responsible for preclinical aspects of advanced therapy medicinal products and biotechnological products since 2006. She has been a member of the EMA Committee for advanced therapies (CAT) 2014-2017, a member of the Cell-based product working party 2008-2012 and an alternate member of the Gene therapy working party 2008-2010. Prior to joining the Finnish medicines agency she worked 13 years in academic research. She graduated from the University of Helsinki 1993, and made her PhD and a post doc in the Dept of Biosciences in the University of Helsinki. 2004-2006 she worked in Biomedicum Helsinki as a senior investigator in basic research aiming at development of human embryonic stem cell–based therapy.